In Part 2 of this discussion, Currien MacDonald, MD, CIP Medical Chair Director for WCG's IRB, discusses new FDA regulations for waiver of consent with Kelly Fitzgerald, PhD, WCG's IRB Executive Chair and VP IBC Affairs.

In Part 2 of this discussion, Currien MacDonald, MD, CIP Medical Chair Director for WCG's IRB, discusses new FDA regulations for waiver of consent with Kelly Fitzgerald, PhD, WCG's IRB Executive Chair and VP IBC Affairs.

In Part 2 of this discussion, Currien MacDonald, MD, CIP Medical Chair Director for WCG's IRB, discusses new FDA regulations for waiver of consent with Kelly Fitzgerald, PhD, WCG's IRB Executive Chair and VP IBC Affairs.&nbsp;

WCG's IRB Policy Change: Harmonizing Consent (Part 2)

Insights from leaders in clinical research and trial optimization, hosted by the WCG Clinical.

Business

Science

Medicine

Health & Fitness

Life Sciences

Insights from leaders in clinical research and trial optimization, hosted by the WCG Clinical.

Share WCG's IRB Policy Change: Harmonizing Consent (Part 2)

Sign up to save your podcasts

WCG's IRB Policy Change: Harmonizing Consent (Part 2)

WCG's IRB Policy Change: Harmonizing Consent (Part 2)